Ipsen: New Patient-Reported Data Demonstrated High Satisfaction Levels and Fewer Patients Reporting Injection-site Pain with Somatuline® Autogel®/Somatuline® Depot (lanreotide)
Retrieved on:
Martedì, Marzo 8, 2022
Medical Supplies, Biotechnology, Other Health, Health, Pharmaceutical, Oncology, Other Science, Medical Devices, Research, Hospitals, Science, Octreotide, Patient, PSP, OCT, Acromegaly, ADR, Conference, Odds ratio, 2021 Essex County Council election, IPN, Pharmaceutical industry, Medical imaging, Ipsen, Euronext, neuroendocrine tumors, PRESTO 2, HomeLAN, Somatuline® Autogel®/Somatuline® Depot (lanreotide), neuroendocrine tumors, PRESTO 2, HomeLAN, Somatuline® Autogel®/Somatuline® Depot (lanreotide), NEUROENDOCRINE TUMORS, PRESTO 2, HOMELAN, SOMATULINE® AUTOGEL®/SOMATULINE® DEPOT (LANREOTIDE)
Presentations include data from the PRESTO 2 and HomeLAN surveys which demonstrated patient-reported benefits when administering Somatuline Autogel/Somatuline Depot (lanreotide).
Key Points:
- Presentations include data from the PRESTO 2 and HomeLAN surveys which demonstrated patient-reported benefits when administering Somatuline Autogel/Somatuline Depot (lanreotide).
- These include fewer patients reporting experiencing injection-site pain and high levels of injection experience satisfaction when participating in patient support programs (PSP), respectively.
- These data will help healthcare professionals better understand the impact of injection-site pain, an important consideration to discuss with patients when making treatment decisions.
- Furthermore, after training, patients on stable dose can administer Somatuline Autogel independently (self or partner), where approved.